Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study

Stephan Petersenn, Andrew J Farrall, Christophe De Block, Christophe Block, Shlomo Melmed, Jochen Schopohl, Philippe Caron, Ross Cuneo, David Kleinberg, Annamaria Colao, Matthieu Ruffin, Karina Hermosillo Reséndiz, Gareth Hughes, Ke Hu, Ariel Barkan

Research output: Contribution to journalArticlepeer-review


Pasireotide has a broader somatostatin receptor binding profile than other somatostatin analogues. A 16-week, Phase II trial showed that pasireotide may be an effective treatment for acromegaly. An extension to this trial assessed the long-term efficacy and safety of pasireotide. This study was an open-label, single-arm, open-ended extension study (primary efficacy and safety evaluated at month 6). Patients could enter the extension if they achieved biochemical control (GH ≤ 2.5 μg/L and normal IGF-1) or showed clinically relevant improvements during the core study. Thirty of the 60 patients who received pasireotide (200-900 μg bid) in the core study entered the extension. At extension month 6, of the 26 evaluable patients, six were biochemically controlled, of whom five had achieved control during the core study. Normal IGF-1 was achieved by 13/26 patients and GH ≤ 2.5 μg/L by 12/26 at month 6. Nine patients received pasireotide for ≥24 months in the extension; three who were biochemically controlled at month 24 had achieved control during the core study. Of 29 patients with MRI data, nine had significant (≥20%) tumor volume reduction during the core study; an additional eight had significant reduction during the extension. The most common adverse events were transient gastrointestinal disturbances; hyperglycemia-related events occurred in 14 patients. Twenty patients had fasting plasma glucose shifted to a higher category during the extension. However, last available glucose measurements were normal for 17 patients. Pasireotide has the potential to be an effective, long-term medical treatment for acromegaly, providing sustained biochemical control and significant reductions in tumor volume.

Original languageEnglish
Pages (from-to)132-40
Number of pages9
Issue number2
Publication statusPublished - Apr 2014


  • Acromegaly
  • Adenoma
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Growth Hormone
  • Growth Hormone-Secreting Pituitary Adenoma
  • Humans
  • Injections, Subcutaneous
  • Insulin-Like Growth Factor I
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Pituitary Neoplasms
  • Somatostatin
  • Treatment Outcome
  • Tumor Burden
  • Young Adult


Dive into the research topics of 'Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study'. Together they form a unique fingerprint.

Cite this